Logo image of AGCB

ALTIMETER GROWTH CORP 2-A (AGCB) Stock Fundamental Analysis

NYSE:AGCB - New York Stock Exchange, Inc. - KYG0371B1095 - Common Stock - Currency: USD

10.105  +0 (+0.05%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to AGCB. AGCB was compared to 0 industry peers in the Unkown industry. The financial health of AGCB is average, but there are quite some concerns on its profitability. AGCB is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

AGCB had positive earnings in the past year.
In the past year AGCB has reported a negative cash flow from operations.
AGCB Yearly Net Income VS EBIT VS OCF VS FCFAGCB Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 -500K -1M -1.5M

1.2 Ratios

Industry RankSector Rank
ROA 0.21%
ROE 0.22%
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
AGCB Yearly ROA, ROE, ROICAGCB Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 -10 -20 -30 -40

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AGCB so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AGCB Yearly Profit, Operating, Gross MarginsAGCB Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021

More info and screens

5

2. Health

2.1 Basic Checks

AGCB has more shares outstanding than it did 1 year ago.
There is no outstanding debt for AGCB. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AGCB Yearly Shares OutstandingAGCB Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 10M 20M 30M 40M 50M
AGCB Yearly Total Debt VS Total AssetsAGCB Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 100M 200M 300M 400M

2.2 Solvency

AGCB has an Altman-Z score of 20.51. This indicates that AGCB is financially healthy and has little risk of bankruptcy at the moment.
AGCB has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 20.51
ROIC/WACCN/A
WACCN/A
AGCB Yearly LT Debt VS Equity VS FCFAGCB Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 0 100M 200M 300M 400M

2.3 Liquidity

AGCB has a Current Ratio of 0.12. This is a bad value and indicates that AGCB is not financially healthy enough and could expect problems in meeting its short term obligations.
A Quick Ratio of 0.12 indicates that AGCB may have some problems paying its short term obligations.
Industry RankSector Rank
Current Ratio 0.12
Quick Ratio 0.12
AGCB Yearly Current Assets VS Current LiabilitesAGCB Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 200K 400K 600K 800K

More info and screens

0

3. Growth

3.1 Past

AGCB shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -10172.76%.
EPS 1Y (TTM)-10172.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.38%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

With a Price/Earnings ratio of 505.25, AGCB can be considered very expensive at the moment.
When comparing the Price/Earnings ratio of AGCB to the average of the S&P500 Index (24.21), we can say AGCB is valued expensively.
Industry RankSector Rank
PE 505.25
Fwd PE N/A
AGCB Price Earnings VS Forward Price EarningsAGCB Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AGCB Per share dataAGCB EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AGCB!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ALTIMETER GROWTH CORP 2-A

NYSE:AGCB (12/20/2022, 8:13:18 PM)

10.105

+0 (+0.05%)

Chartmill FA Rating
GICS SectorN/A
GICS IndustryGroupN/A
GICS IndustryN/A
Earnings (Last)11-25 2022-11-25/bmo
Earnings (Next)N/A N/A
Inst Owners0.55%
Inst Owner Change0%
Ins Owners0.13%
Ins Owner Change0%
Market Cap579.52M
Analysts0
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)N/A
PT rev (3m)N/A
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE 505.25
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 1.33
P/tB 1.33
EV/EBITDA N/A
EPS(TTM)0.02
EY0.2%
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0
BVpS7.6
TBVpS7.6
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA 0.21%
ROE 0.22%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.12
Quick Ratio 0.12
Altman-Z 20.51
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-10172.76%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%88.38%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-15119.9%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A